To include your compound in the COVID-19 Resource Center, submit it here.

Anamorelin: Phase III data

The double-blind, international Phase III ROMANA 2 trial in 477 non-small cell lung cancer (NSCLC) patients with cachexia showed that once-daily 100 mg anamorelin met the co-primary endpoint of increasing median lean

Read the full 324 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE